11/27
02:33 pm
aort
Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Low
Report
Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
11/26
06:07 am
aort
Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q3 Teardown: Artivion (NYSE:AORT) Vs The Rest [Yahoo! Finance]
Low
Report
Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q3 Teardown: Artivion (NYSE:AORT) Vs The Rest [Yahoo! Finance]
11/15
07:05 pm
aort
Strong Q3 Results and Raised Outlook Could Be a Game Changer for Artivion (AORT) [Yahoo! Finance]
Low
Report
Strong Q3 Results and Raised Outlook Could Be a Game Changer for Artivion (AORT) [Yahoo! Finance]
11/11
09:26 am
aort
2 Unpopular Stocks That Deserve a Second Chance and 1 Facing Challenges [Yahoo! Finance]
Medium
Report
2 Unpopular Stocks That Deserve a Second Chance and 1 Facing Challenges [Yahoo! Finance]
11/9
07:03 pm
aort
Artivion (AORT): Is the Healthcare Standout Fairly Valued After Recent Surge? [Yahoo! Finance]
Low
Report
Artivion (AORT): Is the Healthcare Standout Fairly Valued After Recent Surge? [Yahoo! Finance]
11/7
11:01 pm
aort
Artivion's (NYSE:AORT) Q3 Sales Top Estimates [Yahoo! Finance]
Low
Report
Artivion's (NYSE:AORT) Q3 Sales Top Estimates [Yahoo! Finance]
11/7
04:57 pm
aort
Artivion (NYSE:AORT) had its price target raised by analysts at Canaccord Genuity Group Inc. from $50.00 to $51.00. They now have a "buy" rating on the stock.
Low
Report
Artivion (NYSE:AORT) had its price target raised by analysts at Canaccord Genuity Group Inc. from $50.00 to $51.00. They now have a "buy" rating on the stock.
11/7
09:05 am
aort
Artivion (NYSE:AORT) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Medium
Report
Artivion (NYSE:AORT) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
11/7
08:41 am
aort
Artivion (NYSE:AORT) had its price target raised by analysts at Citizens Jmp from $47.00 to $53.00. They now have a "market outperform" rating on the stock.
Medium
Report
Artivion (NYSE:AORT) had its price target raised by analysts at Citizens Jmp from $47.00 to $53.00. They now have a "market outperform" rating on the stock.
11/7
08:07 am
aort
Artivion (NYSE:AORT) had its price target raised by analysts at Needham & Company LLC from $50.00 to $58.00. They now have a "buy" rating on the stock.
Medium
Report
Artivion (NYSE:AORT) had its price target raised by analysts at Needham & Company LLC from $50.00 to $58.00. They now have a "buy" rating on the stock.
11/6
11:47 pm
aort
Artivion outlines double-digit revenue growth target for 2025 as AMDS and On-X momentum builds [Seeking Alpha]
Medium
Report
Artivion outlines double-digit revenue growth target for 2025 as AMDS and On-X momentum builds [Seeking Alpha]
11/6
04:52 pm
aort
Artivion Non-GAAP EPS of $0.16 beats by $0.01, revenue of $113.4M beats by $2.81M [Seeking Alpha]
Medium
Report
Artivion Non-GAAP EPS of $0.16 beats by $0.01, revenue of $113.4M beats by $2.81M [Seeking Alpha]
11/6
04:36 pm
aort
Artivion Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Medium
Report
Artivion Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
11/6
04:05 pm
aort
Artivion Reports Third Quarter 2025 Financial Results
Medium
Report
Artivion Reports Third Quarter 2025 Financial Results
11/6
08:00 am
aort
Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial
Low
Report
Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial
10/31
08:08 pm
aort
Why Artivion (AORT) Is Up 5.2% After Raising Its 2024 Outlook and Highlighting Product Momentum [Yahoo! Finance]
Low
Report
Why Artivion (AORT) Is Up 5.2% After Raising Its 2024 Outlook and Highlighting Product Momentum [Yahoo! Finance]
10/29
04:10 pm
aort
Artivion to Participate in the Stifel 2025 Healthcare Conference
Low
Report
Artivion to Participate in the Stifel 2025 Healthcare Conference
10/23
04:10 pm
aort
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results
Neutral
Report
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results
10/13
08:10 am
aort
Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE and AMDS PROTECT Trials at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting [Yahoo! Finance]
Low
Report
Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE and AMDS PROTECT Trials at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting [Yahoo! Finance]
10/13
08:00 am
aort
Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE and AMDS PROTECT Trials at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting
Low
Report
Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE and AMDS PROTECT Trials at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting
10/10
09:05 am
aort
Artivion (NYSE:AORT) had its price target raised by analysts at JMP Securities from $42.00 to $47.00. They now have a "market outperform" rating on the stock.
Low
Report
Artivion (NYSE:AORT) had its price target raised by analysts at JMP Securities from $42.00 to $47.00. They now have a "market outperform" rating on the stock.
10/10
08:45 am
aort
Artivion (NYSE:AORT) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Artivion (NYSE:AORT) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
10/3
03:30 pm
aort
Artivion (NYSE:AORT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Artivion (NYSE:AORT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/29
11:03 am
aort
Artivion (NYSE:AORT) had its price target raised by analysts at Stifel Nicolaus from $40.00 to $46.00. They now have a "buy" rating on the stock.
Low
Report
Artivion (NYSE:AORT) had its price target raised by analysts at Stifel Nicolaus from $40.00 to $46.00. They now have a "buy" rating on the stock.
9/29
08:31 am
aort
Artivion (NYSE:AORT) had its price target raised by analysts at Canaccord Genuity Group Inc. from $41.00 to $50.00. They now have a "buy" rating on the stock.
Low
Report
Artivion (NYSE:AORT) had its price target raised by analysts at Canaccord Genuity Group Inc. from $41.00 to $50.00. They now have a "buy" rating on the stock.